Symphony Environmental Technologies PLC (LON:SYM) said it received approval from the US Food & Drug Administration (FDA) for its d2p antimicrobial food contact technology alongside much greater loading of the technology and the wider use of its original bread-packaging approval announced in February last year.
The AIM-listed firm said that the FDA’s approval applies to all types of polyolefin and polyester film for wrapping bread, instead of just linear low-density polythene (LLDPE),. As a result, it expects an “acceleration of the commercial process in the near term”.
READ: Symphony Environmental expects to meet full-year expectations
Symphony also said that pre-commercial trials for the US and other countries were already progressing in anticipation of the approval, with data showing “significant benefits” from the further enhanced, and now FDA-approved, d2p treated plastic films.
"This innovative multi-layer film treatment with d2p has been developed through our customer-focused trials following last year's FDA approval. The benefits for our customers were already significant and so we are delighted to have obtained this more enhanced approval for our d2p bread applications in the USA. Symphony already generates significant revenues from the baking industry from our d2w biodegradable technology in plastic packaging, and we are seeing considerable interest in our FDA-approved, d2p antimicrobial technology for bread packaging. d2p is synergistic with d2w biodegradable technology and is expected to be sold to many of our current customers as well as new ones separately, or as a combined treatment”, Symphony chief executive Michael Laurier said in a statement.
“The value proposition is now so much greater with better efficacy and more flexibility. We are confident of announcing the start of commercial sales during this year and in the medium term, generating significant revenues from d2p treated films, not just in the USA, but in other key regions of the world", the CEO added.